
Home » Pipeline
Pipeline
Company | Drug/Device | Medical Condition | Status |
---|---|---|---|
Moderna | mRNA-1273 | coronavirus | vials shipped to NIH for use in phase 1 trial |
Magenta Therapeutics | MGTA-145 | stem cell mobilization needed | completion of dosing in phase 1 trial |
Pandion Therapeutics | PT101 | autoimmune diseases | dosing of first subject in phase 1 trial |
Actinium Pharmaceuticals | Actimab-A 7+3 | acute myeloid leukemia | phase 1 trial dose escalation |
Cyclo Therapeutics | Trappsol Cyclo | Niemann-Pick disease Type C Alzheimer’s disease | patient enrollment completed for phase 1 trial |
Abivax | ABX196 | inflammatory diseases, viral diseases and cancer | dosing of first patient in phase 1/2 trial |
BeiGene SpringWorks (Mapkure) |
BGB-3245 | advanced or refractory solid tumors | initiation of phase 1 trial |
Anokion | KAN-101 | celiac disease | initiation of patient dosing in phase 1 trial |
Neurimmune | NI006 | ATTR cardiomyopathy | initiation of phase 1 trial |
Inflazome | Somalix | harmful inflammation | completion of phase 1 trial |
Sojournix | SJX-653 | menopausal hot flashes | initiation of phase 2 trial |
Ascentage Pharma | APG-1387 | advanced pancreatic cancer | approval of phase 1/2b trial |
CytomX Therapeutics Bristol-Myers Squibb |
BMS-986249 alone and in combination with nivolumab | selected advanced solid tumors | initiated phase 2 expansion of phase 1/2a trial |
Axcella | AXA1665-002 | complex diseases | completed enrollment in phase 2 trial |
Fulcrum Therapeutics | losmapimod | facioscapulohumeral muscular dystrophy | completed patient enrollment in phase 2b trial |
iTeos Therapeutics | EOS-448 | advanced cancers | enrolled first patient in phase 1/2 trial |
Antibe Therapeutics | ATB-346 | osteoarthritis pain | last patient enrolled in phase 2b trial |
Exelixis | CABOMETYX (cabozantinib) | radioactive iodine-refractory differentiated thyroid cancer | phase 3 trial enrolling the first 100 of 300 patients at 150 sites globally |
Marinus Pharmaceuticals | oral ganaxolone | CDKL5 Deficiency Disorder in children and young adults | phase 3 trial initiated enrolling 100 patients |
Gilead Sciences | remdesivir | COVID-19 | two phase 3 trials initiated |
PolyPid | D-PLEX100 | prevention of sternal wound infection after cardiac surgery | phase 3 trial initiated enrolling first patient |
Noxopharm | Veyonda | soft tissue sarcomas | IND approved by the FDA |
Translate Bio | MRT5005 | cystic fibrosis | Fast-Track designation granted by the FDA |
Debiopharm | Debio 1143 | confirmed diagnosis of previously untreated, unresectable locally advanced squamous cell carcinoma of the head and neck | Breakthrough Therapy designation granted by the FDA |
Lundbeck | VYEPTI (eptinezumab-jjmr) | migraine | approved by the FDA |
Eli Lilly | Trulicity (dulaglutide) | major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular (CV) disease or multiple cardiovascular risk factors | new indication approved by the FDA |
Seqirus | FLUAD QUADRIVALENT (Influenza Vaccine, Adjuvanted) | seasonal influenza in individuals age 65 and older | approved by the FDA |
Teva Respiratory | ArmonAir Digihaler (fluticasone propionate) Inhalation Powder) | asthma | approved by the FDA |
Esperion | Nexletol (bempedoic acid) | adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C | approved by the FDA |
Esperion | Nexlizet (bempedoic acid and ezetimibe) | adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C | approved by the FDA |
Puma Biotechnology | neratinib in combination with capecitabine | adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting | supplemental NDA approved by the FDA |
Acacia Pharma | BARHEMSY (amisulpride injection) | Postoperative Nausea and Vomiting | approved by the FDA |
Upcoming Events
-
05Dec
-
14Apr